Work

Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance

Year: 2012

Type: review

Abstract: The progressive elucidation of the molecular pathogenesis of cancer has fueled the rational development of targeted drugs for patient populations stratified by genetic characteristics. Here we discuss general challenges relating to molecular diagnostics and describe predictive biomarkers for personalized cancer medicine. We also highlight resistance mechanisms for epidermal growth factor receptor (EGFR) kinase inhibitors in lung cancer. We envisage a future requiring the use of longitudinal genome sequencing and other omics technologies alongside combinatorial treatment to overcome cellular and molecular heterogeneity and prevent resistance caused by clonal evolution.

Source: Clinical Pharmacology & Therapeutics

DOI: 10.1038/clpt.2012.237

Authors: D Gonzalez de Castro, P A Clarke, B Al-Lazikani, P Workman

Institutions: Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Cancer Research UK

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,410